The promise of an in-house patient access program is compelling: greater control, deeper provider relationships, and a direct hand in getting patients to therapy faster. But the path from vision to execution is lined with decisions that can make or break the effort. We offer some suggestions for consideration based on our experience.
For medical device companies, establishing an in-house patient access program represents a significant strategic commitment. Unlike outsourcing hub services to a third party, owning the function internally means owning everything – the people, the processes, the technology, the compliance infrastructure, and ultimately, the outcomes. That is both the appeal and the risk.
Done well, a high-performing in-house program becomes a competitive differentiator: a direct line to the patient and provider experience. Done poorly, it becomes a source of regulatory exposure, provider frustration, and missed commercial opportunity.
So, what separates companies that get it right from those that struggle? It comes down to planning across the full range of program dimensions.
Start with Strategic Clarity
Before a single standard operating procedure (SOP) is written, leadership must define what success looks like. That means articulating specific, measurable objectives. It means understanding how this program fits into the overall commercialization and market access strategy.
Here are the pillars that every program must address:
- Organizational Readiness & Staffing
- Operations
- Legal & Compliance
- Platform
- Provider & Patient Engagement
- Data & Reporting
- Payer Strategy
Organizational Readiness and Staffing
Most companies underestimate what it takes to staff and sustain a high-performing patient access function. Case managers with real reimbursement expertise are not easy to recruit, and they are even harder to retain in a competitive labor market. Leadership needs to think through organizational structure, compensation and incentive design, and how headcount will scale as patient volumes fluctuate.
Training is equally important. A comprehensive curriculum covering intake protocols, benefits investigation, prior authorization mechanics, and escalation frameworks is not a one-time orientation, it is an ongoing competency development program that must be assessed, documented, and refreshed as policies evolve. The question is not whether you will train your staff, but how you will know they are actually competent and compliant after training is complete.
Operations
Standard operating procedures are the operational DNA of a patient access program. Without them, consistency across case managers is impossible, compliance monitoring is guesswork, and audit defense becomes reactive and expensive.
Every stage of the patient journey, from referral through treatment initiation and beyond, should have a mapped, documented workflow. And because payer policies and regulations change continuously, there must be a disciplined version-control process that keeps SOPs current and ensures staff are always working from the right playbook.
Legal and Compliance
For any company considering an in-house program, the compliance landscape is formidable. HIPAA obligations extend well beyond basic data security. They encompass risk assessments, administrative and technical safeguards, consent and authorization management, incident response procedures, and breach notification protocols. Anti-kickback and inducement regulations require careful guardrails around how the program is designed, communicated, and operationalized.
Sales force activity is among the highest-risk areas for compliance exposure in a patient access program. Representatives operating without clear guardrails around what they can say, what they can do, and what they must document create liability that can be difficult to quantify until it materializes. Companies need written policies governing how sales and field teams interact with the program: what constitutes a permissible referral, how program benefits can be communicated to providers, and what documentation is required to demonstrate that interactions are consistent with anti-kickback safe harbors. These policies need to be reinforced through training, monitored through audit and oversight mechanisms, and updated as regulations evolve. The goal is not to constrain commercial activity but rather to ensure that commercial activity does not inadvertently compromise the program or the company. A well-designed compliance framework for sales engagement is, ultimately, what allows a high-performing patient access program to operate at full intensity without regulatory risk.
To learn more about this complex issue, visit our website digital library to watch our recording with Gardner Law.
Guardrails that Work: Practical Reimbursement Rules for the Field
Platform
Technology platform selection is one of the most consequential decisions in building an in-house patient access program, and it is also one of the most frequently deferred. Companies that launch on spreadsheets and shared inboxes with the intention of implementing “real” technology later almost universally find that retrofitting a platform onto an already operating program is significantly more disruptive than getting it right before go-live. The platform is not just a workflow tool, it is the system of record for every patient interaction, the engine for compliance documentation, and the data source for every KPI the program produces. Getting the platform decision right from the start matters.
Companies building in-house programs have a range of platform options, each with meaningful trade-offs. Custom-built CRM configurations on platforms like Salesforce Health Cloud offer flexibility but require substantial internal IT resources and ongoing development investment. General-purpose case management tools may handle workflow adequately but often lack the reimbursement-specific functionality that patient access programs require. Purpose-built patient access platforms, such as Access Bridge, are designed specifically for hub-style operations and come with pre-built benefits investigation workflows, prior authorization tracking, payer database integrations, and compliance documentation capabilities out of the box. For companies that want the operational control of an in-house model without the burden of building proprietary technology from scratch, a purpose-built platform can meaningfully compress implementation timelines and reduce compliance risk. The right answer depends on program scale, internal technical capabilities, and the complexity of the payer landscape the program will navigate.
Provider and Patient Engagement
A patient access program is only as good as its ability to drive provider engagement and patient enrollment. The sales force is a critical link in this chain. Sales and field teams need a comprehensive training curriculum that equips them to communicate the program accurately, compliantly, and persuasively, with standardized talking points, FAQ documents, and objection-handling guides that keep messaging consistent across every customer interaction. Compliance guardrails for sales communications are not restrictions on commercial effectiveness; they are protections against the regulatory exposure that comes from well-intentioned but undisciplined messaging.
Data and Reporting
The key performance indicators (KPI) framework needs to span multiple dimensions, and companies that manage these programs well treat data as an operational management tool. Patient access KPIs fall into several distinct categories, each of which tells a different part of the program’s performance story.
Enrollment and case progression metrics are the foundation. These include referral-to-enrollment conversion rate, time from referral receipt to enrollment completion, case cycle time from enrollment to therapy initiation, and the percentage of cases that stall or drop out at each stage of the workflow. These metrics reveal where the program is losing patients and where process improvements will have the greatest commercial impact.
Payer-related KPIs are equally critical. Prior authorization approval rates, appeal success rates, and average days to authorization decision are essential. Reimbursement denial rates by payer and denial reason provide the granular insight needed to refine clinical evidence packages and appeals templates over time. On the operational efficiency side, programs should track metrics that help managers identify capacity constraints before they affect patient experience. Finally, sales engagement KPIs, including referral volume by territory, conversion rates by sales representative, and program awareness among target providers, close the loop between commercial execution and program performance. A well-instrumented KPI dashboard creates accountability across every function that touches the patient access process.
Payer Strategy
Prior authorization and appeals management may feel like operational functions, but the most effective programs treat payer interactions as a strategic discipline. That means conducting comprehensive payer mapping before launch, understanding coverage policies, prior authorization requirements, and appeals processes across every target market. It means developing payer-specific appeals strategies and clinical evidence packages that support medical necessity arguments with the rigor each payer requires. And it means building the analytical capability to detect and respond to denial and approval pattern shifts.
Summary
Building a patient access program in-house is a long-term strategic investment. The companies that do it well share a common discipline: they treat every dimension of the program as a genuine design problem, not an operational afterthought. They staff and train with rigor. They build SOPs before they need them and update them consistently. They take compliance seriously enough to let it shape program design, not just audit it after the fact. They choose platform technology that will serve the program at scale, not just survive its first six months. They measure what matters and use data to manage, not just report. And they align payer strategy with clinical and commercial reality. The reward for that level of planning is a program that actually moves the needle AND earns the trust of providers, supports patients through a difficult journey, and builds the kind of durable access infrastructure that becomes a genuine competitive advantage.
JDL Access is poised to help companies make this decision and to implement it. Visit Insights Consulting to learn more.
Please reach out for more information: info@jdlaccess.com
